Clinical trial · Interventional
Assessment of Endocrine and Metabolic Late Effects After Childhood Brain Tumor Treatment
Late Endocrine and Metabolic Consequences of Treatment of Primary Brain Tumors in Childhood
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective, single-group interventional study evaluates endocrine and metabolic late effects in survivors of primary brain tumors treated during childhood. According to the study protocol, participants were prospectively assigned to undergo the Study-Specific Endocrine and Metabolic Late-Effects Assessment. The assessment included anthropometric measurements, repeated blood pressure measurements, clinical endocrine evaluation, fasting laboratory testing, and protocol-defined bone and vascular assessments. The purpose of the study was to identify the frequency and severity of endocrine and metabolic late effects and to evaluate their associations with tumor characteristics, previous cancer treatment, age at diagnosis, and physical functioning.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Neoplasms | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Endocrine System Diseases | — | UNRESOLVED | — |
| Metabolic Diseases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Study-Specific Endocrine and Metabolic Late-Effects Assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Study-Specific Endocrine and Metabolic Late-Effects Assessment
- description
- Participants were prospectively assigned to undergo the protocol-defined endocrine and metabolic late-effects assessment. The assessment included anthropometric measurements, repeated blood pressure measurements, clinical endocrine evaluation, fasting laboratory testing, and protocol-defined bone and vascular assessments.
- interventionNames
- Other: Study-Specific Endocrine and Metabolic Late-Effects Assessment
Primary outcomes (1)
- measure
- Number and Percentage of Participants With at Least One Endocrine or Metabolic Late Effect
- timeFrame
- Baseline
- description
- Number and percentage of participants with at least one endocrine or metabolic late effect identified by the protocol-defined Study-Specific Endocrine and Metabolic Late-Effects Assessment. Late effects were identified using medical history, clinical endocrine evaluation, anthropometric measurements, repeated blood pressure measurements, and laboratory findings, including growth-related, thyroid, gonadal, adrenal, glucose, insulin, lipid, liver, and vitamin D parameters.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 5 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Individuals treated for a primary brain tumor in Slovenia between 2008 and 2018 while aged 0 to 18 years. * Survival for at least 5 years after the diagnosis of a primary brain tumor. * Written informed consent provided by the participant or, when applicable, by a parent or legal guardian. Exclusion Criteria: * Failure to meet the inclusion criteria. * Absence of written informed consent from the participant or, when applicable, from a parent or legal guardian.
References
Publications (0)
Data not yet available